Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 3

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · NCT07654374

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–79 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 3
Target enrollment
1100
US sites recruiting
57
Study start
July 17, 2026
Record last updated
October 20, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.

Being studied: aleniglipron; aleniglipron; aleniglipron; Placebo

Conditions: Obesity; Overweight; Chronic Weight Management; Type2 Diabetes Mellitus

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Signed Informed Consent
  • Have a BMI ≥27.0 kg/m2 at Screening
  • Have a diagnosis of T2DM according to the WHO classification or other locally applicable standards, with HbA1c ≥6.5% (≥53 mmol/mol) to ≤10% (86 mmol/mol) at Screening

Exclusion Criteria

  • Have type 1 diabetes, history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM.
  • Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 180 days prior to Screening.
  • Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
  • Self-reported change in body weight >5 kg (11 pounds) within 3 months before Screening.
  • Have prior or planned surgical or non-surgical treatment for obesity.

Recruiting US locations

  • ACCOMPLISH-2 Research Site

    Birmingham, AL 35242

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Chandler, AZ 85225

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Phoenix, AZ 85028

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Sun City West, AZ 85375

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Tucson, AZ 85741

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Fountain Valley, CA 92708

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    La Jolla, CA 92123

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Rolling Hills Estates, CA 90274

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    San Diego, CA 92108

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Waterbury, CT 06708

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Clearwater, FL 33756

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Fort Myers, FL 33912

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Jacksonville, FL 32216

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Leesburg, FL 34748

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Ocala, FL 34470

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Ocoee, FL 34761

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Atlanta, GA 30329

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Lawrenceville, GA 30046

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Union City, GA 30291

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Woodstock, GA 30189

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Meridian, ID 83646

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Des Moines, IA 50314

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Wichita, KS 67218

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Silver Spring, MD 20901

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Methuen, MA 01844

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Mankato, MN 56001

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Minneapolis, MN 55423

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Gulfport, MS 39503

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Ridgeland, MS 39157

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Chesterfield, MO 63005

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    City of Saint Peters, MO 63303

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Hazelwood, MO 63042

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Springfield, MO 65807

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    St Louis, MO 63141

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Missoula, MT 59804

    Site contact: Medical Director GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    The Bronx, NY 10455

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Charlotte, NC 28210

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Fayetteville, NC 28304

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Morehead City, NC 23730

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Winston-Salem, NC 27104

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Columbus, OH 43213

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Moore, OK 73160

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Tulsa, OK 74133

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Yukon, OK 73099

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Portland, OR 97202

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Philadelphia, PA 19152

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Greer, SC 29651

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Nashville, TN 37203

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Austin, TX 78704

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Farmers Branch, TX 75234

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Houston, TX 77040

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Houston, TX 77054

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    San Antonio, TX 78229

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Wylie, TX 75098

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Manassas, VA 20110

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Suffolk, VA 23435

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

  • ACCOMPLISH-2 Research Site

    Renton, WA 98057

    Site contact: Medical Director · GSBRClinicalTrials@structuretx.com

Study contacts (from the official record)

  • Medical Director · 1-650-457-1959 · GSBRClinicalTrials@structuretx.com
All weight loss studies in Alabama →
A Study of Aleniglipron in Adults With Obesity or Overweight and… (NCT07654374) | Bored Studies